{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:30:07Z","timestamp":1749461407646},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00105-024-05406-8","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T08:03:45Z","timestamp":1725005025000},"page":"781-790","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Januskinaseinhibitoren f\u00fcr dermatologische Erkrankungen","Janus kinase inhibitors for skin disorders"],"prefix":"10.1007","volume":"75","author":[{"given":"Farzan","family":"Solimani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Ghoreschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"1","key":"5406_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi\u00a0K, Laurence\u00a0A, O\u2019Shea\u00a0JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273\u2013287","journal-title":"Immunol Rev"},{"issue":"4","key":"5406_CR2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ni.1701","volume":"10","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi\u00a0K, Laurence\u00a0A, O\u2019Shea\u00a0JJ (2009) Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 10(4):356\u2013360","journal-title":"Nat Immunol"},{"issue":"1","key":"5406_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20140712","volume":"462","author":"JJ Babon","year":"2014","unstructured":"Babon\u00a0JJ, Lucet\u00a0IS, Murphy\u00a0JM, Nicola\u00a0NA, Varghese\u00a0LN (2014) The molecular regulation of Janus kinase (JAK) activation. Biochem\u00a0J 462(1):1\u201313","journal-title":"Biochem J"},{"issue":"2","key":"5406_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","volume":"83","author":"M Bonelli","year":"2024","unstructured":"Bonelli\u00a0M, Kerschbaumer\u00a0A, Kastrati\u00a0K, Ghoreschi\u00a0K, Gadina\u00a0M, Heinz\u00a0LX et\u00a0al (2024) Selectivity, efficacy and safety of JAKinibs: new evidence for a\u00a0still evolving story. Ann Rheum Dis 83(2):139\u2013160","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5406_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0952-7915(00)00228-4","volume":"13","author":"M Gadina","year":"2001","unstructured":"Gadina\u00a0M, Hilton\u00a0D, Johnston\u00a0JA, Morinobu\u00a0A, Lighvani\u00a0A, Zhou\u00a0YJ et\u00a0al (2001) Signaling by type\u00a0I and\u00a0II cytokine receptors: ten years after. Curr Opin Immunol 13(3):363\u2013373","journal-title":"Curr Opin Immunol"},{"issue":"10275","key":"5406_CR6","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi\u00a0K, Balato\u00a0A, Enerback\u00a0C, Sabat\u00a0R (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397(10275):754\u2013766","journal-title":"Lancet"},{"issue":"1","key":"5406_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger\u00a0S, Beck\u00a0LA, Bieber\u00a0T, Kabashima\u00a0K, Irvine\u00a0AD (2018) Atopic dermatitis. Nat Rev Dis Primers 4(1):1","journal-title":"Nat Rev Dis Primers"},{"key":"5406_CR8","doi-asserted-by":"crossref","unstructured":"Shao S, Tsoi LC, Sarkar MK, Xing X, Xue K, Uppala R et\u00a0al (2019) IFN-gamma enhances cell-mediated cytotoxicity against keratinocytes via JAK\u00a02\/STAT1 in lichen planus. Sci Transl Med 11(511)","DOI":"10.1126\/scitranslmed.aav7561"},{"issue":"2","key":"5406_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/exd.14226","volume":"30","author":"K Pietschke","year":"2021","unstructured":"Pietschke\u00a0K, Holstein\u00a0J, Meier\u00a0K, Schafer\u00a0I, Muller-Hermelink\u00a0E, Gonzalez-Menendez\u00a0I et\u00a0al (2021) The inflammation in cutaneous lichen planus is dominated by IFN-Upsilon and IL-21\u2014A basis for therapeutic JAK\u00a01 inhibition. Exp Dermatol 30(2):262\u2013270","journal-title":"Exp Dermatol"},{"key":"5406_CR10","doi-asserted-by":"crossref","unstructured":"Solimani F, Mesas-Fernandez A, Dilling A, Nast A, Hilke FJ, Ghoreschi FC et\u00a0al (2023) The Janus kinase\u00a01 inhibitor abrocitinib for the treatment of oral lichen planus. J\u00a0Eur Acad Dermatol Venereol","DOI":"10.1111\/jdv.19069"},{"issue":"4","key":"5406_CR11","doi-asserted-by":"publisher","first-page":"e15080","DOI":"10.1111\/exd.15080","volume":"33","author":"KN Stolte","year":"2024","unstructured":"Stolte\u00a0KN, Mesas-Fernandez\u00a0A, Meier\u00a0K, Klein\u00a0EK, Dommisch\u00a0H, Ghoreschi\u00a0K et\u00a0al (2024) TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus. Exp Dermatol 33(4):e15080","journal-title":"Exp Dermatol"},{"issue":"18","key":"5406_CR12","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood-2017-06-792614","volume":"131","author":"S Takahashi","year":"2018","unstructured":"Takahashi\u00a0S, Hashimoto\u00a0D, Hayase\u00a0E, Ogasawara\u00a0R, Ohigashi\u00a0H, Ara\u00a0T et\u00a0al (2018) Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. Blood 131(18):2074\u20132085","journal-title":"Blood"},{"issue":"4","key":"5406_CR13","first-page":"374","volume":"21","author":"H Bonnekoh","year":"2023","unstructured":"Bonnekoh\u00a0H, Erpenbeck\u00a0L (2023) Neutrophilic dermatoses\u2014Pathomechanistic concepts and therapeutic developments. J\u00a0Dtsch Dermatol Ges 21(4):374\u2013380","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"5406_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","volume":"42","author":"ME Dowty","year":"2014","unstructured":"Dowty\u00a0ME, Lin\u00a0J, Ryder\u00a0TF, Wang\u00a0W, Walker\u00a0GS, Vaz\u00a0A et\u00a0al (2014) The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a\u00a0janus kinase inhibitor, in humans. Drug Metab Dispos 42(4):759\u2013773","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"5406_CR15","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi\u00a0K, Jesson\u00a0MI, Li\u00a0X, Lee\u00a0JL, Ghosh\u00a0S, Alsup\u00a0JW et\u00a0al (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J\u00a0Immunol 186(7):4234\u20134243","journal-title":"J Immunol"},{"issue":"16","key":"5406_CR16","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease\u00a0P, Hall\u00a0S, FitzGerald\u00a0O, van der Heijde\u00a0D, Merola\u00a0JF, Avila-Zapata\u00a0F et\u00a0al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N\u00a0Engl J Med 377(16):1537\u20131550","journal-title":"N Engl J Med"},{"issue":"16","key":"5406_CR17","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman\u00a0D, Rigby\u00a0W, Azevedo\u00a0VF, Behrens\u00a0F, Blanco\u00a0R, Kaszuba\u00a0A et\u00a0al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N\u00a0Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"issue":"2","key":"5406_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson\u00a0EL, Lacour\u00a0JP, Spelman\u00a0L, Galimberti\u00a0R, Eichenfield\u00a0LF, Bissonnette\u00a0R et\u00a0al (2020) Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase\u00a0III trials. Br J Dermatol 183(2):242\u2013255","journal-title":"Br J Dermatol"},{"issue":"1","key":"5406_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson\u00a0EL, Forman\u00a0S, Silverberg\u00a0JI, Zirwas\u00a0M, Maverakis\u00a0E, Han\u00a0G et\u00a0al (2021) Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a\u00a0randomized monotherapy phase\u00a03\u00a0trial in the United States and Canada (BREEZE-AD5). J\u00a0Am Acad Dermatol 85(1):62\u201370","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"5406_CR20","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich\u00a0K, Kabashima\u00a0K, Peris\u00a0K, Silverberg\u00a0JI, Eichenfield\u00a0LF, Bieber\u00a0T et\u00a0al (2020) Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A\u00a0Randomized Clinical Trial. JAMA Dermatol 156(12):1333\u20131343","journal-title":"JAMA Dermatol"},{"issue":"18","key":"5406_CR21","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King\u00a0B, Ohyama\u00a0M, Kwon\u00a0O, Zlotogorski\u00a0A, Ko\u00a0J, Mesinkovska\u00a0NA et\u00a0al (2022) Two phase\u00a03 trials of baricitinib for alopecia areata. N\u00a0Engl J Med 386(18):1687\u20131699","journal-title":"N Engl J Med"},{"issue":"1","key":"5406_CR22","first-page":"275","volume":"10","author":"IB McInnes","year":"2023","unstructured":"McInnes\u00a0IB, Kato\u00a0K, Magrey\u00a0M, Merola\u00a0JF, Kishimoto\u00a0M, Haaland\u00a0D et\u00a0al (2023) Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2\u2011Year Results from the Phase\u00a03 SELECT-PsA 1 Study. Rheumatol Ther 10(1):275\u2013292","journal-title":"Rheumatol Ther"},{"issue":"3","key":"5406_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease\u00a0PJ, Lertratanakul\u00a0A, Anderson\u00a0JK, Papp\u00a0K, Van den Bosch\u00a0F, Tsuji\u00a0S et\u00a0al (2021) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 80(3):312\u2013320","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5406_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky\u00a0E, Thaci\u00a0D, Pangan\u00a0AL, Hong\u00a0HC, Papp\u00a0KA, Reich\u00a0K et\u00a0al (2020) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a\u00a0randomized, placebo-controlled trial. J\u00a0Allergy Clin Immunol 145(3):877\u2013884","journal-title":"J Allergy Clin Immunol"},{"issue":"10290","key":"5406_CR25","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky\u00a0E, Teixeira\u00a0HD, Simpson\u00a0EL, Papp\u00a0KA, Pangan\u00a0AL, Blauvelt\u00a0A et\u00a0al (2021) Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up\u00a02): results from two replicate double-blind, randomised controlled phase\u00a03\u00a0trials. Lancet 397(10290):2151\u20132168","journal-title":"Lancet"},{"issue":"10","key":"5406_CR26","first-page":"1409","volume":"19","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi\u00a0K, Augustin\u00a0M, Baraliakos\u00a0X, Kronke\u00a0G, Schneider\u00a0M, Schreiber\u00a0S et\u00a0al (2021) TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. J\u00a0Dtsch Dermatol Ges 19(10):1409\u20131420","journal-title":"J Dtsch Dermatol Ges"},{"issue":"17","key":"5406_CR27","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","volume":"82","author":"HSM Deucravacitinib","year":"2022","unstructured":"Deucravacitinib\u00a0HSM (2022) First Approval. Drugs 82(17):1671\u20131679","journal-title":"Drugs"},{"issue":"1","key":"5406_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cts.13435","volume":"16","author":"IM Catlett","year":"2023","unstructured":"Catlett\u00a0IM, Aras\u00a0U, Hansen\u00a0L, Liu\u00a0Y, Bei\u00a0D, Girgis\u00a0IG et\u00a0al (2023) First-in-human study of deucravacitinib: A\u00a0selective, potent, allosteric small-molecule inhibitor of tyrosine kinase\u00a02. Clin Transl Sci 16(1):151\u2013164","journal-title":"Clin Transl Sci"},{"issue":"1","key":"5406_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong\u00a0AW, Gooderham\u00a0M, Warren\u00a0RB, Papp\u00a0KA, Strober\u00a0B, Thaci\u00a0D et\u00a0al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1\u00a0trial. J\u00a0Am Acad Dermatol 88(1):29\u201339","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5406_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober\u00a0B, Thaci\u00a0D, Sofen\u00a0H, Kircik\u00a0L, Gordon\u00a0KB, Foley\u00a0P et\u00a0al (2023) Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase\u00a03 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J\u00a0Am Acad Dermatol 88(1):40\u201351","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5406_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","volume":"81","author":"PJ Mease","year":"2022","unstructured":"Mease\u00a0PJ, Deodhar\u00a0AA, van der Heijde\u00a0D, Behrens\u00a0F, Kivitz\u00a0AJ, Neal\u00a0J et\u00a0al (2022) Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a\u00a0phase\u00a0II trial in psoriatic arthritis. Ann Rheum Dis 81(6):815\u2013822","journal-title":"Ann Rheum Dis"},{"issue":"18","key":"5406_CR32","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks\u00a0ED, Duggan\u00a0S (2021) Abrocitinib: First Approval. Drugs 81(18):2149\u20132157","journal-title":"Drugs"},{"issue":"10","key":"5406_CR33","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/jcph.1858","volume":"61","author":"EQ Wang","year":"2021","unstructured":"Wang\u00a0EQ, Le\u00a0V, O\u2019Gorman\u00a0M, Tripathy\u00a0S, Dowty\u00a0ME, Wang\u00a0L et\u00a0al (2021) Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. J\u00a0Clin Pharmacol 61(10):1311\u20131323","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"5406_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/jcph.1980","volume":"62","author":"EQ Wang","year":"2022","unstructured":"Wang\u00a0EQ, Le\u00a0V, Winton\u00a0JA, Tripathy\u00a0S, Raje\u00a0S, Wang\u00a0L et\u00a0al (2022) Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites. J\u00a0Clin Pharmacol 62(4):505\u2013519","journal-title":"J Clin Pharmacol"},{"issue":"10246","key":"5406_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson\u00a0EL, Sinclair\u00a0R, Forman\u00a0S, Wollenberg\u00a0A, Aschoff\u00a0R, Cork\u00a0M et\u00a0al (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a\u00a0multicentre, double-blind, randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet 396(10246):255\u2013266","journal-title":"Lancet"},{"issue":"1","key":"5406_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40257-023-00810-7","volume":"25","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch\u00a0G, Gooderham\u00a0MJ, Stander\u00a0S, Fonacier\u00a0L, Szepietowski\u00a0JC, Deleuran\u00a0M et\u00a0al (2024) Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A\u00a0Post Hoc Analysis of JADE MONO\u20112. Am J Clin Dermatol 25(1):127\u2013138","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"5406_CR37","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich\u00a0K, Silverberg\u00a0JI, Papp\u00a0KA, Deleuran\u00a0M, Katoh\u00a0N, Strober\u00a0B et\u00a0al (2023) Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase\u00a03\u00a0studies, including the long-term extension JADE EXTEND study. J\u00a0Eur Acad Dermatol Venereol 37(10):2056\u20132066","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"14","key":"5406_CR38","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","volume":"83","author":"BHA Ritlecitinib","year":"2023","unstructured":"Ritlecitinib\u00a0BHA (2023) First Approval. Drugs 83(14):1315\u20131321","journal-title":"Drugs"},{"issue":"6","key":"5406_CR39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu\u00a0H, Jesson\u00a0MI, Seneviratne\u00a0UI, Lin\u00a0TH, Sharif\u00a0MN, Xue\u00a0L et\u00a0al (2019) PF-06651600, a\u00a0Dual JAK\u00a03\/TEC Family Kinase Inhibitor. ACS Chem Biol 14(6):1235\u20131242","journal-title":"ACS Chem Biol"},{"issue":"10387","key":"5406_CR40","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King\u00a0B, Zhang\u00a0X, Harcha\u00a0WG, Szepietowski\u00a0JC, Shapiro\u00a0J, Lynde\u00a0C et\u00a0al (2023) Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a\u00a0randomised, double-blind, multicentre, phase\u00a02b-3\u00a0trial. Lancet 401(10387):1518\u20131529","journal-title":"Lancet"},{"issue":"2","key":"5406_CR41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King\u00a0B, Guttman-Yassky\u00a0E, Peeva\u00a0E, Banerjee\u00a0A, Sinclair\u00a0R, Pavel\u00a0AB et\u00a0al (2021) A\u00a0phase\u00a02a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J\u00a0Am Acad Dermatol 85(2):379\u2013387","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5406_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/pde.15378","volume":"40","author":"M Hordinsky","year":"2023","unstructured":"Hordinsky\u00a0M, Hebert\u00a0AA, Gooderham\u00a0M, Kwon\u00a0O, Murashkin\u00a0N, Fang\u00a0H et\u00a0al (2023) Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase\u00a02b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol 40(6):1003\u20131009","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"5406_CR43","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","volume":"149","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky\u00a0E, Pavel\u00a0AB, Diaz\u00a0A, Zhang\u00a0N, Del Duca\u00a0E, Estrada\u00a0Y et\u00a0al (2022) Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J\u00a0Allergy Clin Immunol 149(4):1318\u20131328","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"5406_CR44","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","volume":"76","author":"B Rothstein","year":"2017","unstructured":"Rothstein\u00a0B, Joshipura\u00a0D, Saraiya\u00a0A, Abdat\u00a0R, Ashkar\u00a0H, Turkowski\u00a0Y et\u00a0al (2017) Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J\u00a0Am Acad Dermatol 76(6):1054\u20131060.e1","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5406_CR45","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","volume":"78","author":"D Joshipura","year":"2018","unstructured":"Joshipura\u00a0D, Alomran\u00a0A, Zancanaro\u00a0P, Rosmarin\u00a0D (2018) Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A\u00a032-week open-label extension study with optional narrow-band ultraviolet B. J\u00a0Am Acad Dermatol 78(6):1205\u20131207","journal-title":"J Am Acad Dermatol"},{"issue":"10244","key":"5406_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin\u00a0D, Pandya\u00a0AG, Lebwohl\u00a0M, Grimes\u00a0P, Hamzavi\u00a0I, Gottlieb\u00a0AB et\u00a0al (2020) Ruxolitinib cream for treatment of vitiligo: a\u00a0randomised, controlled, phase\u00a02\u00a0trial. Lancet 396(10244):110\u2013120","journal-title":"Lancet"},{"issue":"16","key":"5406_CR47","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","volume":"387","author":"D Rosmarin","year":"2022","unstructured":"Rosmarin\u00a0D, Passeron\u00a0T, Pandya\u00a0AG, Grimes\u00a0P, Harris\u00a0JE, Desai\u00a0SR et\u00a0al (2022) Two phase\u00a03, randomized, controlled trials of ruxolitinib cream for vitiligo. N\u00a0Engl J Med 387(16):1445\u20131455","journal-title":"N Engl J Med"},{"issue":"19","key":"5406_CR48","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","volume":"61","author":"A Fensome","year":"2018","unstructured":"Fensome\u00a0A, Ambler\u00a0CM, Arnold\u00a0E, Banker\u00a0ME, Brown\u00a0MF, Chrencik\u00a0J et\u00a0al (2018) Dual Inhibition of TYK2 and JAK\u00a01 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1\u202fR,5 S)-3-(2-((1-methyl-1\u202fH-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J\u00a0Med Chem 61(19):8597\u20138612","journal-title":"J Med Chem"},{"issue":"6","key":"5406_CR49","doi-asserted-by":"publisher","first-page":"100156","DOI":"10.1016\/j.xjidi.2022.100156","volume":"2","author":"B King","year":"2022","unstructured":"King\u00a0B, Guttman-Yassky\u00a0E, Peeva\u00a0E, Banerjee\u00a0A, Zhu\u00a0L, Zhu\u00a0H et\u00a0al (2022) Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase\u00a02a Trial. JID Innov 2(6):100156","journal-title":"JID Innov"},{"issue":"2","key":"5406_CR50","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","volume":"87","author":"E Peeva","year":"2022","unstructured":"Peeva\u00a0E, Guttman-Yassky\u00a0E, Banerjee\u00a0A, Sinclair\u00a0R, Cox\u00a0LA, Zhu\u00a0L et\u00a0al (2022) Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a\u00a0single-blind extension of a\u00a0phase\u00a02a randomized clinical trial. J\u00a0Am Acad Dermatol 87(2):390\u2013393","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"5406_CR51","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.42519","volume":"75","author":"P Mease","year":"2023","unstructured":"Mease\u00a0P, Helliwell\u00a0P, Silwinska-Stanczyk\u00a0P, Miakisz\u00a0M, Ostor\u00a0A, Peeva\u00a0E et\u00a0al (2023) Efficacy and Safety of the TYK2\/JAK\u00a01 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A\u00a0Phase\u00a0IIb Randomized Controlled Trial. Arthritis Rheumatol 75(8):1370\u20131380","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"5406_CR52","doi-asserted-by":"publisher","first-page":"EVIDoa2300155","DOI":"10.1056\/EVIDoa2300155","volume":"3","author":"AB Kimball","year":"2024","unstructured":"Kimball\u00a0AB, Peeva\u00a0E, Forman\u00a0S, Moiin\u00a0A, Khattri\u00a0S, Porter\u00a0ML et\u00a0al (2024) Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa. NEJM Evid 3(3):EVIDoa2300155","journal-title":"NEJM Evid"},{"issue":"6","key":"5406_CR53","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bjd.21826","volume":"187","author":"MN Landis","year":"2022","unstructured":"Landis\u00a0MN, Arya\u00a0M, Smith\u00a0S, Draelos\u00a0Z, Usdan\u00a0L, Tarabar\u00a0S et\u00a0al (2022) Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a\u00a0phase\u00a0IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br J Dermatol 187(6):878\u2013887","journal-title":"Br J Dermatol"},{"issue":"3","key":"5406_CR54","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"JS Kirby","year":"2024","unstructured":"Kirby\u00a0JS, Okun\u00a0MM, Alavi\u00a0A, Bechara\u00a0FG, Zouboulis\u00a0CC, Brown\u00a0K et\u00a0al (2024) Efficacy and safety of the oral Janus kinase\u00a01 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a\u00a0phase\u00a02, randomized, double-blind, dose-ranging, placebo-controlled study. J\u00a0Am Acad Dermatol 90(3):521\u2013529","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"5406_CR55","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjd.20969","volume":"186","author":"A Alavi","year":"2022","unstructured":"Alavi\u00a0A, Hamzavi\u00a0I, Brown\u00a0K, Santos\u00a0LL, Zhu\u00a0Z, Liu\u00a0H et\u00a0al (2022) Janus kinase\u00a01 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase\u00a0II studies. Br J Dermatol 186(5):803\u2013813","journal-title":"Br J Dermatol"},{"issue":"3","key":"5406_CR56","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","volume":"136","author":"W Amano","year":"2015","unstructured":"Amano\u00a0W, Nakajima\u00a0S, Kunugi\u00a0H, Numata\u00a0Y, Kitoh\u00a0A, Egawa\u00a0G et\u00a0al (2015) The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J\u00a0Allergy Clin Immunol 136(3):667\u2013677","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"5406_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","volume":"64","author":"A Tanimoto","year":"2015","unstructured":"Tanimoto\u00a0A, Ogawa\u00a0Y, Oki\u00a0C, Kimoto\u00a0Y, Nozawa\u00a0K, Amano\u00a0W et\u00a0al (2015) Pharmacological properties of JTE-052: a\u00a0novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res 64(1):41\u201351","journal-title":"Inflamm Res"},{"issue":"1","key":"5406_CR58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/bjd.21037","volume":"187","author":"M Worm","year":"2022","unstructured":"Worm\u00a0M, Thyssen\u00a0JP, Schliemann\u00a0S, Bauer\u00a0A, Shi\u00a0VY, Ehst\u00a0B et\u00a0al (2022) The pan-JAK inhibitor delgocitinib in a\u00a0cream formulation demonstrates dose response in chronic hand eczema in a\u00a016-week randomized phase\u00a0IIb trial. Br J Dermatol 187(1):42\u201351","journal-title":"Br J Dermatol"},{"issue":"5","key":"5406_CR59","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.18469","volume":"182","author":"M Worm","year":"2020","unstructured":"Worm\u00a0M, Bauer\u00a0A, Elsner\u00a0P, Mahler\u00a0V, Molin\u00a0S, Nielsen\u00a0TSS (2020) Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a\u00a0randomized, double-blind, vehicle-controlled phase\u00a0IIa study. Br J Dermatol 182(5):1103\u20131110","journal-title":"Br J Dermatol"},{"issue":"18","key":"5406_CR60","first-page":"1768","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Connell\u00a0CA (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Reply. N\u00a0Engl J Med 386(18):1768","journal-title":"N Engl J Med"},{"issue":"5","key":"5406_CR61","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson\u00a0EL, Silverberg\u00a0JI, Nosbaum\u00a0A, Winthrop\u00a0KL, Guttman-Yassky\u00a0E, Hoffmeister\u00a0KM et\u00a0al (2021) Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase\u00a0II and Phase\u00a0III Clinical Trial Program. Am J Clin Dermatol 22(5):693\u2013707","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"5406_CR62","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/ibd\/izy160","volume":"24","author":"U Mahadevan","year":"2018","unstructured":"Mahadevan\u00a0U, Dubinsky\u00a0MC, Su\u00a0C, Lawendy\u00a0N, Jones\u00a0TV, Marren\u00a0A et\u00a0al (2018) Outcomes of Pregnancies With Maternal\/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. Inflamm Bowel Dis 24(12):2494\u20132500","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"5406_CR63","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","volume":"39","author":"ME Clowse","year":"2016","unstructured":"Clowse\u00a0ME, Feldman\u00a0SR, Isaacs\u00a0JD, Kimball\u00a0AB, Strand\u00a0V, Warren\u00a0RB et\u00a0al (2016) Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Saf 39(8):755\u2013762","journal-title":"Drug Saf"},{"issue":"6","key":"5406_CR64","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci\u00a0JL, Xu\u00a0B, Qiu\u00a0Y, Wu\u00a0TJ, Dada\u00a0H, Twyman-Saint\u00a0VC et\u00a0al (2016) Tumor Interferon Signaling Regulates a\u00a0Multigenic Resistance Program to Immune Checkpoint Blockade. Cell 167(6):1540\u20131554","journal-title":"Cell"},{"issue":"6702","key":"5406_CR65","doi-asserted-by":"publisher","first-page":"eadf1329","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew\u00a0D, Marmarelis\u00a0ME, Foley\u00a0C, Bauml\u00a0JM, Ye\u00a0D, Ghinnagow\u00a0R et\u00a0al (2024) Combined JAK inhibition and PD\u20111 immunotherapy for non-small cell lung cancer patients. Science 384(6702):eadf1329","journal-title":"Science"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-024-05406-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-024-05406-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T14:04:15Z","timestamp":1727791455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-024-05406-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5406"],"URL":"https:\/\/doi.org\/10.1007\/s00105-024-05406-8","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"type":"print","value":"2731-7005"},{"type":"electronic","value":"2731-7013"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"22 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Solimani und K.\u00a0Ghoreschi geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}